

In the Claims:

- 1-14. (cancelled).
15. (cancelled).
16. (cancelled).
17. (currently amended) A method of claim ~~15~~ 21, wherein the antibody is AJH10 secreted by a hybridoma designated as ATCC PTA-3580.
18. (currently amended) A method of claim ~~16~~ 22, wherein the antibody is AJH10 secreted by a hybridoma designated as ATCC PTA-3580.
19. (currently amended) A method of claim ~~15~~ 21, wherein the antibody is a human antibody, a chimeric antibody, a humanized antibody, a monoclonal antibody, or a polyclonal antibody.
20. (currently amended) A method of claim ~~16~~ 22, wherein the antibody is a human antibody, a chimeric antibody, a humanized antibody, a monoclonal antibody, or a polyclonal antibody.
21. (currently amended) A method ~~of claim 15, wherein the antibody is for the treatment of rheumatoid arthritis comprising administering to a subject suffering from rheumatoid arthritis a therapeutically effective amount of an anti- α 1-I domain blocking antibody and, wherein~~ of claim 15, wherein the antibody is for the treatment of rheumatoid arthritis comprising administering to a subject suffering from rheumatoid arthritis a therapeutically effective amount of an anti- α 1-I domain blocking antibody and, wherein the amino acid sequence of the antibody epitope comprises the sequence Val-Gln-Arg-Gly-Gly-Arg (SEQ ID NO: 8) ~~or an amino acid sequence that is equivalent or homologous to such sequence.~~
22. (currently amended) A method ~~of claim 16, wherein the antibody is for inhibiting or preventing rheumatoid arthritis comprising administering to a subject at risk of developing or suffering from rheumatoid arthritis a therapeutically effective amount of an anti- α 1-I domain blocking antibody and, wherein~~ of claim 16, wherein the antibody is for inhibiting or preventing rheumatoid arthritis comprising administering to a subject at risk of developing or suffering from rheumatoid arthritis a therapeutically effective amount of an anti- α 1-I domain blocking antibody and, wherein the amino acid sequence of the antibody epitope comprises the sequence Val-Gln-Arg-Gly-Gly-Arg (SEQ ID NO: 8) ~~or an amino acid sequence that is equivalent or homologous to such sequence.~~
23. (cancelled).

24. (new) A method for the treatment of rheumatoid arthritis comprising administering to a subject suffering from rheumatoid arthritis a therapeutically effective amount of an antibody molecule comprising antigen binding regions derived from the light and heavy chain variable regions of an antibody to an $\alpha 1\beta 1$ integrin, wherein the antibody is AJH10, which is secreted by a hybridoma designated as ATCC PTA-3580.
25. (new) A method for inhibiting or preventing rheumatoid arthritis comprising administering to a subject at risk of developing or suffering from rheumatoid arthritis a therapeutically effective amount of an antibody molecule comprising antigen binding regions derived from the light and heavy chain variable regions of an antibody to an $\alpha 1\beta 1$ integrin, wherein the antibody is AJH10, which is secreted by a hybridoma designated as ATCC PTA-3580.